Skip to main content

Advertisement

Log in

Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group

  • Review Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Cancer-related cognitive impairment (CRCI) is commonly experienced by individuals with non-central nervous system cancers throughout the disease and treatment trajectory. CRCI can have a substantial impact on the functional ability and quality of life of patients and their families. To mitigate the impact, oncology providers must know how to identify, assess, and educate patients and caregivers. The objective of this review is to provide oncology clinicians with an overview of CRCI in the context of adults with non-central nervous system cancers, with a particular focus on current approaches in its identification, assessment, and management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data Availability

Not Applicable

References

  1. Wefel JS, Kesler SR, Noll KR, Schagen SB (2015) Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin 65(2):123–138. https://doi.org/10.3322/caac.21258

    Article  PubMed  Google Scholar 

  2. Lange M, Licaj I, Clarisse B, Humbert X, Grellard JM, Tron L, Joly F (2019) Cognitive complaints in cancer survivors and expectations for support: Results from a web-based survey. Cancer Med 8(5):2654–2663. https://doi.org/10.1002/cam4.2069

    Article  PubMed  PubMed Central  Google Scholar 

  3. Von Ah D, Storey S, Tallman E, Nielsen A, Johns SA, Pressler S (2016) Cancer, cognitive impairment, and work-related outcomes: an integrative review. Oncol Nurs Forum 43(5):602–616. https://doi.org/10.1188/16.onf.602-616

    Article  Google Scholar 

  4. Potrata B, Cavet J, Blair S, Howe T, Molassiotis A (2010) 'Like a sieve': an exploratory study on cognitive impairments in patients with multiple myeloma. Eur J Cancer Care 19(6):721–728. https://doi.org/10.1111/j.1365-2354.2009.01145.x

    Article  CAS  Google Scholar 

  5. Shilling V, Jenkins V (2007) Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs 11(1):6–15. https://doi.org/10.1016/j.ejon.2006.02.005

    Article  PubMed  Google Scholar 

  6. Boykoff N, Moieni M, Subramanian SK (2009) Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response. J Cancer Surviv 3(4):223–232. https://doi.org/10.1007/s11764-009-0098-x

    Article  PubMed  PubMed Central  Google Scholar 

  7. Mayo S, Messner HA, Rourke SB, Howell D, Victor JC, Kuruvilla J, Lipton JH, Gupta V, Kim DD, Piescic C, Breen D, Lambie A, Loach D, Michelis FV, Alam N, Uhm J, McGillis L, Metcalfe K (2016) Relationship between neurocognitive functioning and medication management ability over the first 6 months following allogeneic stem cell transplantation. Bone Marrow Transplant 51(6):841–847. https://doi.org/10.1038/bmt.2016.2

    Article  CAS  PubMed  Google Scholar 

  8. Anderson-Hanley C, Sherman ML, Riggs R, Agocha VB, Compas BE (2003) Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc 9(7):967–982. https://doi.org/10.1017/S1355617703970019

    Article  PubMed  Google Scholar 

  9. Kelly DL, Buchbinder D, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick A, Wirk BM, Yi J, Battiwalla M, Flowers ME, Savani B, Shaw BE (2018) Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and quality of life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 24(2):228–241. https://doi.org/10.1016/j.bbmt.2017.09.004

    Article  PubMed  Google Scholar 

  10. Phillips KM, McGinty HL, Cessna J, Asvat Y, Gonzalez B, Cases MG, Small BJ, Jacobsen PB, Pidala J, Jim HS (2013) A systematic review and meta-analysis of changes in cognitive functioning in adults undergoing hematopoietic cell transplantation. Bone Marrow Transplant 48(10):1350–1357. https://doi.org/10.1038/bmt.2013.61

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Williams AM, Zent CS, Janelsins MC (2016) What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research. Br J Haematol 174(6):835–846. https://doi.org/10.1111/bjh.14211

    Article  PubMed  PubMed Central  Google Scholar 

  12. Treanor CJ, Li J, Donnelly M (2017) Cognitive impairment among prostate cancer patients: an overview of reviews. Eur J Cancer Care 26(6). https://doi.org/10.1111/ecc.12642

  13. Janelsins MC, Kesler SR, Ahles TA, Morrow GR (2014) Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry (Abingdon, England) 26(1):102–113. https://doi.org/10.3109/09540261.2013.864260

    Article  PubMed Central  Google Scholar 

  14. Schmidt J, Beckjord E, Bovbjerg D, Low C, Posluszny D, Lowery A, Dew M, Nutt S, Arvey S, Rechis R (2015) Prevalence of perceived cognitive dysfunction in survivors of a wide range of cancers: results from the 2010 LIVESTRONG survey. J Cancer Surviv:1–10. https://doi.org/10.1007/s11764-015-0476-5

  15. Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB (2008) Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 19(4):623–629. https://doi.org/10.1093/annonc/mdm500

    Article  CAS  PubMed  Google Scholar 

  16. Mehnert A, Scherwath A, Schirmer L, Schleimer B, Petersen C, Schulz-Kindermann F, Zander AR, Koch U (2007) The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. Patient Educ Couns 66(1):108–118. https://doi.org/10.1016/j.pec.2006.11.005

    Article  PubMed  Google Scholar 

  17. Santos JC, Pyter LM (2018) Neuroimmunology of behavioral comorbidities associated with cancer and cancer treatments. Front Immunol 9:1195. https://doi.org/10.3389/fimmu.2018.01195

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Jansen CE, Cooper BA, Dodd MJ, Miaskowski CA (2011) A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer 19(10):1647–1656. https://doi.org/10.1007/s00520-010-0997-4

    Article  PubMed  Google Scholar 

  19. Vardy JL, Dhillon HM, Pond GR, Rourke SB, Bekele T, Renton C, Dodd A, Zhang H, Beale P, Clarke S, Tannock IF (2015) Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol 33(34):4085–4092. https://doi.org/10.1200/jco.2015.63.0905

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Wefel JS, Vidrine DJ, Veramonti TL, Meyers CA, Marani SK, Hoekstra HJ, Hoekstra-Weebers JE, Shahani L, Gritz ER (2011) Cognitive impairment in men with testicular cancer prior to adjuvant therapy. Cancer 117(1):190–196. https://doi.org/10.1002/cncr.25298

    Article  PubMed  Google Scholar 

  21. Piai V, Prins JB, Verdonck-de Leeuw IM, Leemans CR, Terhaard CHJ, Langendijk JA, Baatenburg de Jong RJ, Smit JH, Takes RP, Kessels RPC (2019) Assessment of neurocognitive impairment and speech functioning before head and neck cancer treatment. JAMA Otolaryngol Head Neck Surg. https://doi.org/10.1001/jamaoto.2018.3981

  22. Hshieh TT, Jung WF, Grande LJ, Chen J, Stone RM, Soiffer RJ, Driver JA, Abel GA (2018) Prevalence of cognitive impairment and association with survival among older patients with hematologic cancers. JAMA Oncol 4(5):686–693. https://doi.org/10.1001/jamaoncol.2017.5674

    Article  PubMed  PubMed Central  Google Scholar 

  23. Simo M, Rifa-Ros X, Rodriguez-Fornells A, Bruna J (2013) Chemobrain: a systematic review of structural and functional neuroimaging studies. Neurosci Biobehav Rev 37(8):1311–1321. https://doi.org/10.1016/j.neubiorev.2013.04.015

    Article  PubMed  Google Scholar 

  24. Jim HS, Phillips KM, Chait S, Faul LA, Popa MA, Lee YH, Hussin MG, Jacobsen PB, Small BJ (2012) Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol 30(29):3578–3587. https://doi.org/10.1200/jco.2011.39.5640

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Ono M, Ogilvie JM, Wilson JS, Green HJ, Chambers SK, Ownsworth T, Shum DH (2015) A meta-analysis of cognitive impairment and decline associated with adjuvant chemotherapy in women with breast cancer. Front Oncol 5:59. https://doi.org/10.3389/fonc.2015.00059

    Article  PubMed  PubMed Central  Google Scholar 

  26. Hodgson KD, Hutchinson AD, Wilson CJ, Nettelbeck T (2013) A meta-analysis of the effects of chemotherapy on cognition in patients with cancer. Cancer Treat Rev 39(3):297–304. https://doi.org/10.1016/j.ctrv.2012.11.001

    Article  CAS  PubMed  Google Scholar 

  27. Janelsins MC, Heckler CE, Peppone LJ, Kamen C, Mustian KM, Mohile SG, Magnuson A, Kleckner IR, Guido JJ, Young KL, Conlin AK, Weiselberg LR, Mitchell JW, Ambrosone CA, Ahles TA, Morrow GR (2017) Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: an analysis from a nationwide, multicenter, prospective longitudinal study. J Clin Oncol 35(5):506–514. https://doi.org/10.1200/jco.2016.68.5826

    Article  PubMed  Google Scholar 

  28. Janelsins MC, Heckler CE, Peppone LJ, Ahles TA, Mohile SG, Mustian KM, Palesh O, O'Mara AM, Minasian LM, Williams AM, Magnuson A, Geer J, Dakhil SR, Hopkins JO, Morrow GR (2018) Longitudinal trajectory and characterization of cancer-related cognitive impairment in a nationwide cohort study. J Clin Oncol:Jco2018786624. https://doi.org/10.1200/jco.2018.78.6624

  29. Hosseini SM, Koovakkattu D, Kesler SR (2012) Altered small-world properties of gray matter networks in breast cancer. BMC Neurol 12:28. https://doi.org/10.1186/1471-2377-12-28

    Article  PubMed  PubMed Central  Google Scholar 

  30. Penson RT, Kronish K, Duan Z, Feller AJ, Stark P, Cook SE, Duska LR, Fuller AF, Goodman AK, Nikrui N, MacNeill KM, Matulonis UA, Preffer FI, Seiden MV (2000) Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 10(1):33–41. https://doi.org/10.1046/j.1525-1438.2000.00003.x

    Article  PubMed  Google Scholar 

  31. Pendergrass JC, Targum SD, Harrison JE (2018) Cognitive impairment associated with cancer: a brief review. Innov Clin Neurosci 15(1-2):36–44

    PubMed  PubMed Central  Google Scholar 

  32. McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ (2010) Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat 123(3):819–828. https://doi.org/10.1007/s10549-010-1088-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Geraghty AC, Gibson EM, Ghanem RA, Greene JJ, Ocampo A, Goldstein AK, Ni L, Yang T, Marton RM, Pasca SP, Greenberg ME, Longo FM, Monje M (2019) Loss of adaptive myelination contributes to methotrexate chemotherapy-related cognitive impairment. Neuron 103(2):250–265.e258. https://doi.org/10.1016/j.neuron.2019.04.032

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Gibson EM, Nagaraja S, Ocampo A, Tam LT, Wood LS, Pallegar PN, Greene JJ, Geraghty AC, Goldstein AK, Ni L, Woo PJ, Barres BA, Liddelow S, Vogel H, Monje M (2019) Methotrexate chemotherapy induces persistent tri-glial dysregulation that underlies chemotherapy-related cognitive impairment. Cell 176(1-2):43–55.e13. https://doi.org/10.1016/j.cell.2018.10.049

    Article  CAS  PubMed  Google Scholar 

  35. Rogers LR (2012) Neurologic complications of radiation. Continuum (Minneap Minn) 18(2):343–54. https://doi.org/10.1212/01.CON.0000413662.35174

    Article  PubMed  Google Scholar 

  36. Wilke C, Grosshans D, Duman J, Brown P, Li J (2018) Radiation-induced cognitive toxicity: pathophysiology and interventions to reduce toxicity in adults. Neuro-Oncology 20(5):597–607. https://doi.org/10.1093/neuonc/nox195

    Article  CAS  PubMed  Google Scholar 

  37. Dong X, Luo M, Huang G, Zhang J, Tong F, Cheng Y, Cai Q, Dong J, Wu G, Cheng J (2015) Relationship between irradiation-induced neuro-inflammatory environments and impaired cognitive function in the developing brain of mice. Int J Radiat Biol 91(3):224–239. https://doi.org/10.3109/09553002.2014.988895

    Article  CAS  PubMed  Google Scholar 

  38. Carvalho HA, Villar RC (2018) Radiotherapy and immune response: the systemic effects of a local treatment. Clinics (Sao Paulo, Brazil) 73(suppl 1):e557s–e557s. https://doi.org/10.6061/clinics/2018/e557s

    Article  Google Scholar 

  39. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454. https://doi.org/10.1056/NEJMoa1200690

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. McGinnis GJ, Raber J (2017) CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy. Immunotherapy 9(11):929–941. https://doi.org/10.2217/imt-2017-0056

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. McGinnis GJ, Friedman D, Young KH, Torres ER, Thomas CR Jr, Gough MJ, Raber J (2017) Neuroinflammatory and cognitive consequences of combined radiation and immunotherapy in a novel preclinical model. Oncotarget 8(6):9155–9173. https://doi.org/10.18632/oncotarget.13551

    Article  PubMed  Google Scholar 

  42. Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V, Kluger HM (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17(7):976–983. https://doi.org/10.1016/s1470-2045(16)30053-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Joly F, Castel H, Tron L, Lange M, Vardy J (2020) Potential effect of immunotherapy agents on cognitive function in cancer patients. J Natl Cancer Inst 112(2):123–127. https://doi.org/10.1093/jnci/djz168

    Article  CAS  PubMed  Google Scholar 

  44. Fathpour P, Obad N, Espedal H, Stieber D, Keunen O, Sakariassen PO, Niclou SP, Bjerkvig R (2014) Bevacizumab treatment for human glioblastoma. Can it induce cognitive impairment? Neuro-Oncol 16(5):754–756. https://doi.org/10.1093/neuonc/nou013

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699–708. https://doi.org/10.1056/NEJMoa1308573

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Ng T, Phey XY, Yeo HL, Shwe M, Gan YX, Ng R, Ho HK, Chan A (2018) Impact of adjuvant anthracycline-based and taxane-based chemotherapy on plasma VEGF levels and cognitive function in breast cancer patients: a longitudinal study. Clin Breast Cancer 18(5):e927–e937. https://doi.org/10.1016/j.clbc.2018.03.016

    Article  CAS  PubMed  Google Scholar 

  47. Mulder SF, Bertens D, Desar IM, Vissers KC, Mulders PF, Punt CJ, van Spronsen DJ, Langenhuijsen JF, Kessels RP, van Herpen CM (2014) Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study. BMC Cancer 14:219. https://doi.org/10.1186/1471-2407-14-219

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Wick W, Hertenstein A, Platten M (2016) Neurological sequelae of cancer immunotherapies and targeted therapies. Lancet Oncol 17(12):e529–e541. https://doi.org/10.1016/S1470-2045(16)30571-X

    Article  PubMed  Google Scholar 

  49. Ulm M, Ramesh AV, McNamara KM, Ponnusamy S, Sasano H, Narayanan R (2019) Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers. Endocr Connect 8(2):R10–r26. https://doi.org/10.1530/ec-18-0425

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Luine VN (2014) Estradiol and cognitive function: past, present and future. Horm Behav 66(4):602–618. https://doi.org/10.1016/j.yhbeh.2014.08.011

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Bean LA, Ianov L, Foster TC (2014) Estrogen receptors, the hippocampus, and memory. Neuroscientist 20(5):534–545. https://doi.org/10.1177/1073858413519865

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Bender CM, Merriman JD, Gentry AL, Ahrendt GM, Berga SL, Brufsky AM, Casillo FE, Dailey MM, Erickson KI, Kratofil FM, McAuliffe PF, Rosenzweig MQ, Ryan CM, Sereika SM (2015) Patterns of change in cognitive function with anastrozole therapy. Cancer 121(15):2627–2636. https://doi.org/10.1002/cncr.29393

    Article  CAS  PubMed  Google Scholar 

  53. Ganz PA, Petersen L, Bower JE, Crespi CM (2016) Impact of adjuvant endocrine therapy on quality of life and symptoms: observational data over 12 months from the mind-body study. J Clin Oncol 34(8):816–824. https://doi.org/10.1200/JCO.2015.64.3866

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB (2010) Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol 28(8):1294–1300. https://doi.org/10.1200/JCO.2008.21.3553

    Article  CAS  PubMed  Google Scholar 

  55. Underwood EA, Jerzak KJ, Lebovic G, Rochon PA, Elser C, Pritchard KI, Tierney MC (2019) Cognitive effects of adjuvant endocrine therapy in older women treated for early-stage breast cancer: a 1-year longitudinal study. Support Care Cancer. https://doi.org/10.1007/s00520-018-4603-5

  56. Van Dyk K, Crespi CM, Bower JE, Castellon SA, Petersen L, Ganz PA (2019) The cognitive effects of endocrine therapy in survivors of breast cancer: A prospective longitudinal study up to 6 years after treatment. Cancer 125(5):681–689. https://doi.org/10.1002/cncr.31858

    Article  CAS  PubMed  Google Scholar 

  57. Salminen EK, Portin RI, Koskinen AI, Helenius HY, Nurmi MJ (2005) Estradiol and cognition during androgen deprivation in men with prostate carcinoma. Cancer 103(7):1381–1387. https://doi.org/10.1002/cncr.20962

    Article  PubMed  Google Scholar 

  58. Sharafeldin N, Bosworth A, Patel SK, Chen Y, Morse E, Mather M, Sun C, Francisco L, Forman SJ, Wong FL, Bhatia S (2018) Cognitive functioning after hematopoietic cell transplantation for hematologic malignancy: results from a prospective longitudinal study. J Clin Oncol 36(5):463–475. https://doi.org/10.1200/jco.2017.74.2270

    Article  CAS  PubMed  Google Scholar 

  59. Syrjala KL, Artherholt SB, Kurland BF, Langer SL, Roth-Roemer S, Elrod JB, Dikmen S (2011) Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years. J Clin Oncol. https://doi.org/10.1200/jco.2010.33.9119

  60. Reid-Arndt SA, Cox CR (2012) Stress, coping and cognitive deficits in women after surgery for breast cancer. J Clin Psychol Med Settings 19(2):127–137. https://doi.org/10.1007/s10880-011-9274-z

    Article  PubMed  Google Scholar 

  61. Cimprich B, Reuter-Lorenz P, Nelson J, Clark PM, Therrien B, Normolle D, Berman MG, Hayes DF, Noll DC, Peltier S, Welsh RC (2010) Prechemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol 32(3):324–331. https://doi.org/10.1080/13803390903032537

    Article  PubMed  Google Scholar 

  62. Su Y, Pu Y, Zhao Z, Yang X (2020) Influence of combined epidural anesthesia on cognitive function, inflammation and stress response in elderly liver cancer patients undergoing surgery. Oncol Lett 19(4):2733–2738. https://doi.org/10.3892/ol.2020.11395

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Mandelblatt JS, Stern RA, Luta G, McGuckin M, Clapp JD, Hurria A, Jacobsen PB, Faul LA, Isaacs C, Denduluri N, Gavett B, Traina TA, Johnson P, Silliman RA, Turner RS, Howard D, Van Meter JW, Saykin A, Ahles T (2014) Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity? J Clin Oncol 32(18):1909–1918. https://doi.org/10.1200/jco.2013.54.2050

    Article  PubMed  PubMed Central  Google Scholar 

  64. Mayo S, Messner HA, Rourke SB, Howell D, Victor JC, Kuruvilla J, Lipton JH, Gupta V, Kim DDH, McGillis L, Uhm J, Michelis FV, Alam N, Lambie A, Breen D, Loach D, Piescic C, Metcalfe K (2015) Predictors of the trajectory of neurocognitive functioning in the first six months after allogeneic hematopoietic stem cell transplantation. Blood 126(23):3289

    Article  Google Scholar 

  65. Jim HSL, Small B, Hartman S, Franzen J, Millay S, Phillips K, Jacobsen PB, Booth-Jones M, Pidala J (2012) Clinical predictors of cognitive function in adults treated with hematopoietic cell transplantation. Cancer 118(13):3407–3416

    Article  PubMed  Google Scholar 

  66. McQuillan R, Jassal SV (2010) Neuropsychiatric complications of chronic kidney disease. Nat Rev Nephrol 6(8):471–479. https://doi.org/10.1038/nrneph.2010.83

    Article  PubMed  Google Scholar 

  67. Watanabe K, Watanabe T, Nakayama M (2014) Cerebro-renal interactions: impact of uremic toxins on cognitive function. Neurotoxicology 44:184–193. https://doi.org/10.1016/j.neuro.2014.06.014

    Article  CAS  PubMed  Google Scholar 

  68. Collie A (2005) Cognition in liver disease. Liver Int 25(1):1–8. https://doi.org/10.1111/j.1478-3231.2005.01012.x

    Article  PubMed  Google Scholar 

  69. Huskisson E, Maggini S, Ruf M (2007) The influence of micronutrients on cognitive function and performance. J Int Med Res 35(1):1–19. https://doi.org/10.1177/147323000703500101

    Article  CAS  PubMed  Google Scholar 

  70. Miller JW, Harvey DJ, Beckett LA, Green R, Farias ST, Reed BR, Olichney JM, Mungas DM, DeCarli C (2015) Vitamin D status and rates of cognitive decline in a multiethnic cohort of older adults. JAMA Neurol 72(11):1295–1303. https://doi.org/10.1001/jamaneurol.2015.2115

    Article  PubMed  PubMed Central  Google Scholar 

  71. Wittbrodt MT, Millard-Stafford M (2018) Dehydration impairs cognitive performance: a meta-analysis. Med Sci Sports Exerc 50(11):2360–2368. https://doi.org/10.1249/mss.0000000000001682

    Article  PubMed  Google Scholar 

  72. Van Cutsem E, Arends J (2005) The causes and consequences of cancer-associated malnutrition. Eur J Oncol Nurs 9(Suppl 2):S51–S63. https://doi.org/10.1016/j.ejon.2005.09.007

    Article  PubMed  Google Scholar 

  73. Rosner MH, Dalkin AC (2014) Electrolyte disorders associated with cancer. Adv Chronic Kidney Dis 21(1):7–17. https://doi.org/10.1053/j.ackd.2013.05.005

    Article  PubMed  Google Scholar 

  74. Mancuso A, Migliorino M, De Santis S, Saponiero A, De Marinis F (2006) Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy. Ann Oncol 17(1):146–150. https://doi.org/10.1093/annonc/mdj038

    Article  CAS  PubMed  Google Scholar 

  75. Massa E, Madeddu C, Lusso MR, Gramignano G, Mantovani G (2006) Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy. Crit Rev Oncol Hematol 57(2):175–182. https://doi.org/10.1016/j.critrevonc.2005.06.001

    Article  PubMed  Google Scholar 

  76. Iconomou G, Koutras A, Karaivazoglou K, Kalliolias GD, Assimakopoulos K, Argyriou AA, Ifanti A, Kalofonos HP (2008) Effect of epoetin alpha therapy on cognitive function in anaemic patients with solid tumours undergoing chemotherapy. Eur J Cancer Care 17(6):535–541. https://doi.org/10.1111/j.1365-2354.2007.00857.x

    Article  CAS  Google Scholar 

  77. Fan HG, Park A, Xu W, Yi QL, Braganza S, Chang J, Couture F, Tannock IF (2009) The influence of erythropoietin on cognitive function in women following chemotherapy for breast cancer. Psychooncology 18(2):156–161. https://doi.org/10.1002/pon.1372

    Article  PubMed  Google Scholar 

  78. Von Ah D, Jansen CE, Allen DH (2014) Evidence-based interventions for cancer- and treatment-related cognitive impairment. Clin J Oncol Nurs 18(Suppl):17–25. https://doi.org/10.1188/14.cjon.s3.17-25

    Article  Google Scholar 

  79. Ahles TA, Saykin AJ, Noll WW, Furstenberg CT, Guerin S, Cole B, Mott LA (2003) The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psycho-oncology 12(6):612–619. https://doi.org/10.1002/pon.742

    Article  PubMed  Google Scholar 

  80. Mandelblatt JS, Small BJ, Luta G, Hurria A, Jim H, McDonald BC, Graham D, Zhou X, Clapp J, Zhai W, Breen E, Carroll JE, Denduluri N, Dilawari A, Extermann M, Isaacs C, Jacobsen PB, Kobayashi LC, Holohan Nudelman K, Root J, Stern RA, Tometich D, Turner R, VanMeter JW, Saykin AJ, Ahles T (2018) Cancer-related cognitive outcomes among older breast cancer survivors in the thinking and living with cancer study. J Clin Oncol:Jco1800140. https://doi.org/10.1200/jco.18.00140

  81. Amidi A, Agerbaek M, Wu LM, Pedersen AD, Mehlsen M, Clausen CR, Demontis D, Borglum AD, Harboll A, Zachariae R (2017) Changes in cognitive functions and cerebral grey matter and their associations with inflammatory markers, endocrine markers, and APOE genotypes in testicular cancer patients undergoing treatment. Brain Imaging Behav 11(3):769–783. https://doi.org/10.1007/s11682-016-9552-3

    Article  PubMed  Google Scholar 

  82. Cheng H, Li W, Gan C, Zhang B, Jia Q, Wang K (2016) The COMT (rs165599) gene polymorphism contributes to chemotherapy-induced cognitive impairment in breast cancer patients. Am J Transl Res 8(11):5087–5097

    CAS  PubMed  PubMed Central  Google Scholar 

  83. Small BJ, Rawson KS, Walsh E, Jim HS, Hughes TF, Iser L, Andrykowski MA, Jacobsen PB (2011) Catechol-O-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors. Cancer 117(7):1369–1376. https://doi.org/10.1002/cncr.25685

    Article  CAS  PubMed  Google Scholar 

  84. Ng T, Teo SM, Yeo HL, Shwe M, Gan YX, Cheung YT, Foo KM, Cham MT, Lee JA, Tan YP, Fan G, Yong WS, Preetha M, Loh WJ, Koo SL, Jain A, Lee GE, Wong M, Dent R, Yap YS, Ng R, Khor CC, Ho HK, Chan A (2016) Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer. Neuro Oncol 18(2):244–251. https://doi.org/10.1093/neuonc/nov162

    Article  CAS  PubMed  Google Scholar 

  85. Tan CJ, Lim SWT, Toh YL, Ng T, Yeo A, Shwe M, Foo KM, Chu P, Jain A, Koo SL, Dent RA, Ng RCH, Yap YS, Lim EH, Loh KW, Chay WY, Lee GE, Tan TJY, Beh SY, Wong M, Chan JJ, Khor CC, Ho HK, Chan A (2018) Replication and Meta-analysis of the Association between BDNF Val66Met Polymorphism and Cognitive Impairment in Patients Receiving Chemotherapy. Mol Neurobiol. https://doi.org/10.1007/s12035-018-1410-4

  86. Chan A, Yeo A, Shwe M, Tan CJ, Foo KM, Chu P, Khor CC, Ho HK (2019) An Evaluation of DNA Methyltransferase 1 (DNMT1) Single nucleotide polymorphisms and chemotherapy-associated cognitive impairment: a prospective, longitudinal study. Sci Rep 9(1):14570. https://doi.org/10.1038/s41598-019-51203-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Ownby KK (2019) Use of the distress thermometer in clinical practice. J Adv Pract Oncol 10(2):175–179

    PubMed  PubMed Central  Google Scholar 

  88. Cormio C, Caporale F, Spatuzzi R, Lagattolla F, Lisi A, Graziano G (2019) Psychosocial distress in oncology: using the distress thermometer for assessing risk classes. Support Care Cancer 27(11):4115–4121. https://doi.org/10.1007/s00520-019-04694-4

    Article  PubMed  Google Scholar 

  89. National Comprehensive Cancer Network (2014) Survivorship, Version 2.2014. NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network

  90. Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, Group obotEQoL (2001) The EORTC QLQ-C30 Scoring Manual, 3rd edn. European Organisation for Research and Treatment of Cancer, Brussels

    Google Scholar 

  91. Giesinger JM, Loth FLC, Aaronson NK, Arraras JI, Caocci G, Efficace F, Groenvold M, van Leeuwen M, Petersen MA, Ramage J, Tomaszewski KA, Young T, Holzner B (2020) Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. J Clin Epidemiol 118:1–8. https://doi.org/10.1016/j.jclinepi.2019.10.003

    Article  PubMed  Google Scholar 

  92. Wagner L, Sweet J, Butt Z, Lai J, Cella D (2009) Measuring patient self-reported cognitive function: development of the functional assessment of cancer therapy-cognitive function instrument. J Support Oncol 7:32–39

    Google Scholar 

  93. Bray VJ, Dhillon HM, Vardy JL (2018) Systematic review of self-reported cognitive function in cancer patients following chemotherapy treatment. J Cancer Surviv 12(4):537–559. https://doi.org/10.1007/s11764-018-0692-x

    Article  PubMed  Google Scholar 

  94. Mohile SG, Dale W, Somerfield MR, Schonberg MA, Boyd CM, Burhenn PS, Canin B, Cohen HJ, Holmes HM, Hopkins JO, Janelsins MC, Khorana AA, Klepin HD, Lichtman SM, Mustian KM, Tew WP, Hurria A (2018) Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol 36(22):2326–2347. https://doi.org/10.1200/jco.2018.78.8687

    Article  PubMed  PubMed Central  Google Scholar 

  95. (1996) Mini-Mental State Examination (MMSE) and the Modified MMSE (3MS): a psychometric comparison and normative data, vol 8. American Psychological Association, US. https://doi.org/10.1037/1040-3590.8.1.48

  96. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53(4):695–699. https://doi.org/10.1111/j.1532-5415.2005.53221.x

    Article  PubMed  Google Scholar 

  97. Isenberg-Grzeda E, Huband H, Lam H (2017) A review of cognitive screening tools in cancer. Curr Opin Support Palliat Care 11(1):24–31

    Article  PubMed  Google Scholar 

  98. Saria MG, Courchesne N, Evangelista L, Carter J, MacManus DA, Gorman MK, Nyamathi AM, Phillips LR, Piccioni D, Kesari S, Maliski S (2017) Cognitive dysfunction in patients with brain metastases: influences on caregiver resilience and coping. Support Care Cancer 25(4):1247–1256. https://doi.org/10.1007/s00520-016-3517-3

    Article  PubMed  Google Scholar 

  99. Kang JH, Shin SH, Bruera E (2013) Comprehensive approaches to managing delirium in patients with advanced cancer. Cancer Treat Rev 39(1):105–112. https://doi.org/10.1016/j.ctrv.2012.08.001

    Article  PubMed  Google Scholar 

  100. Pereira J, Hanson J, Bruera E (1997) The frequency and clinical course of cognitive impairment in patients with terminal cancer. Cancer 79(4):835–842

    Article  CAS  PubMed  Google Scholar 

  101. Harada CN, Natelson Love MC, Triebel KL (2013) Normal cognitive aging. Clin Geriatr Med 29(4):737–752. https://doi.org/10.1016/j.cger.2013.07.002

    Article  PubMed  PubMed Central  Google Scholar 

  102. Ahles TA, Hurria A (2018) New Challenges in Psycho-Oncology Research IV: cognition and cancer: Conceptual and methodological issues and future directions. Psycho-oncology 27(1):3–9. https://doi.org/10.1002/pon.4564

    Article  PubMed  Google Scholar 

  103. Guida JL, Ahles TA, Belsky D, Campisi J, Cohen HJ, DeGregori J, Fuldner R, Ferrucci L, Gallicchio L, Gavrilov L, Gavrilova N, Green PA, Jhappan C, Kohanski R, Krull K, Mandelblatt J, Ness KK, O’Mara A, Price N, Schrack J, Studenski S, Theou O, Tracy RP, Hurria A (2019) Measuring aging and identifying aging phenotypes in cancer survivors. J Natl Cancer Inst 111(12):1245–1254. https://doi.org/10.1093/jnci/djz136

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Cheung YT, Tan EH-J, Chan A (2012) An evaluation on the neuropsychological tests used in the assessment of postchemotherapy cognitive changes in breast cancer survivors. Support Care Cancer 20(7):1361–1375. https://doi.org/10.1007/s00520-012-1445-4

    Article  PubMed  Google Scholar 

  105. Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C (2012) Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev 38(7):926–934. https://doi.org/10.1016/j.ctrv.2012.05.002

    Article  PubMed  Google Scholar 

  106. Wefel JS, Vardy J, Ahles T, Schagen SB (2011) International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12(7):703–708. https://doi.org/10.1016/S1470-2045(10)70294-1

    Article  PubMed  Google Scholar 

  107. Lange M, Joly F (2017) How to identify and manage cognitive dysfunction after breast cancer treatment. J Oncol Practice 13(12):784–790. https://doi.org/10.1200/jop.2017.026286

    Article  Google Scholar 

  108. Miller JB, Barr WB (2017) The technology crisis in neuropsychology. Arch Clin Neuropsychol 32(5):541–554. https://doi.org/10.1093/arclin/acx050

    Article  PubMed  Google Scholar 

  109. Poppelreuter M, Weis J, Kulz AK, Tucha O, Lange KW, Bartsch HH (2004) Cognitive dysfunction and subjective complaints of cancer patients. a cross-sectional study in a cancer rehabilitation centre. Eur J Cancer 40(1):43–49. https://doi.org/10.1016/j.ejca.2003.08.001

    Article  CAS  PubMed  Google Scholar 

  110. Srisurapanont M, Suttajit S, Eurviriyanukul K, Varnado P (2017) Discrepancy between objective and subjective cognition in adults with major depressive disorder. Sci Rep 7(1):3901. https://doi.org/10.1038/s41598-017-04353-w

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Kim HJ, Barsevick AM, Fang CY, Miaskowski C (2012) Common biological pathways underlying the psychoneurological symptom cluster in cancer patients. Cancer Nurs 35(6):E1–e20. https://doi.org/10.1097/NCC.0b013e318233a811

    Article  PubMed  Google Scholar 

  112. Von Ah D, Storey S, Jansen CE, Allen DH (2013) Coping strategies and interventions for cognitive changes in patients with cancer. Semin Oncol Nurs 29(4):288–299. https://doi.org/10.1016/j.soncn.2013.08.009

    Article  Google Scholar 

  113. Green HJ, Mihuta ME, Ownsworth T, Dhillon HM, Tefay M, Sanmugarajah J, Tuffaha HW, Ng SK, Shum DHK (2019) Adaptations to cognitive problems reported by breast cancer survivors seeking cognitive rehabilitation: A qualitative study. Psycho-oncology 28(10):2042–2048. https://doi.org/10.1002/pon.5189

    Article  PubMed  Google Scholar 

  114. Meneses K, Benz R, Bail JR, Vo JB, Triebel K, Fazeli P, Frank J, Vance DE (2018) Speed of processing training in middle-aged and older breast cancer survivors (SOAR): results of a randomized controlled pilot. Breast Cancer Res Treat 168(1):259–267. https://doi.org/10.1007/s10549-017-4564-2

    Article  PubMed  Google Scholar 

  115. Damholdt MF, Mehlsen M, O'Toole MS, Andreasen RK, Pedersen AD, Zachariae R (2016) Web-based cognitive training for breast cancer survivors with cognitive complaints-a randomized controlled trial. Psycho-oncology 25(11):1293–1300. https://doi.org/10.1002/pon.4058

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Kesler S, Hadi Hosseini SM, Heckler C, Janelsins M, Palesh O, Mustian K, Morrow G (2013) Cognitive training for improving executive function in chemotherapy-treated breast cancer survivors. Clinical breast cancer 13(4):299–306. https://doi.org/10.1016/j.clbc.2013.02.004

    Article  PubMed  PubMed Central  Google Scholar 

  117. Bray VJ, Dhillon HM, Bell ML, Kabourakis M, Fiero MH, Yip D, Boyle F, Price MA, Vardy JL (2016) Evaluation of a web-based cognitive rehabilitation program in cancer survivors reporting cognitive symptoms after chemotherapy. J Clin Oncol 35(2):217–225. https://doi.org/10.1200/JCO.2016.67.8201

    Article  PubMed  Google Scholar 

  118. Von Ah D, Carpenter JS, Saykin A, Monahan P, Wu J, Yu M, Rebok G, Ball K, Schneider B, Weaver M, Tallman E, Unverzagt F (2012) Advanced cognitive training for breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat 135(3):799–809. https://doi.org/10.1007/s10549-012-2210-6

    Article  Google Scholar 

  119. Wu LM, Amidi A, Tanenbaum ML, Winkel G, Gordon WA, Hall SJ, Bovbjerg K, Diefenbach MA (2018) Computerized cognitive training in prostate cancer patients on androgen deprivation therapy: a pilot study. Support Care Cancer 26(6):1917–1926. https://doi.org/10.1007/s00520-017-4026-8

    Article  PubMed  Google Scholar 

  120. Cherrier MM, Anderson K, David D, Higano CS, Gray H, Church A, Willis SL (2013) A randomized trial of cognitive rehabilitation in cancer survivors. Life Sci 93(17):617–622. https://doi.org/10.1016/j.lfs.2013.08.011

    Article  CAS  PubMed  Google Scholar 

  121. Ercoli LM, Petersen L, Hunter AM, Castellon SA, Kwan L, Kahn-Mills BA, Embree LM, Cernin PA, Leuchter AF, Ganz PA (2015) Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial. Psycho-oncology 24(11):1360–1367. https://doi.org/10.1002/pon.3769

    Article  CAS  PubMed  Google Scholar 

  122. King S, Green HJ (2015) Psychological intervention for improving cognitive function in cancer survivors: a literature review and randomized controlled trial. Front Oncol 5:72. https://doi.org/10.3389/fonc.2015.00072

    Article  PubMed  PubMed Central  Google Scholar 

  123. Green HJ, Tefay M, Mihuta ME (2018) Feasibility of small group cognitive rehabilitation in a clinical cancer setting. Psycho-oncology 27(4):1341–1343. https://doi.org/10.1002/pon.4600

    Article  PubMed  Google Scholar 

  124. Mihuta ME, Green HJ, Shum DHK (2018) Efficacy of a web-based cognitive rehabilitation intervention for adult cancer survivors: a pilot study. Eur J Cancer Care 27(2):e12805. https://doi.org/10.1111/ecc.12805

    Article  CAS  Google Scholar 

  125. Schuurs A, Green HJ (2013) A feasibility study of group cognitive rehabilitation for cancer survivors: enhancing cognitive function and quality of life. Psychooncology 22(5):1043–1049. https://doi.org/10.1002/pon.3102

    Article  PubMed  Google Scholar 

  126. Von Ah D, Crouch A (2020) Cognitive rehabilitation for cognitive dysfunction after cancer and cancer treatment: implications for nursing practice. Semin Oncol Nurs 36(1):150977. https://doi.org/10.1016/j.soncn.2019.150977

    Article  Google Scholar 

  127. Fernandes HA, Richard NM, Edelstein K (2019) Cognitive rehabilitation for cancer-related cognitive dysfunction: a systematic review. Support Care Cancer 27(9):3253–3279. https://doi.org/10.1007/s00520-019-04866-2

    Article  PubMed  Google Scholar 

  128. Zimmer P, Baumann FT, Oberste M, Wright P, Garthe A, Schenk A, Elter T, Galvao DA, Bloch W, Hubner ST, Wolf F (2016) Effects of exercise interventions and physical activity behavior on cancer related cognitive impairments: a systematic review. Biomed Res Int 2016:1820954. https://doi.org/10.1155/2016/1820954

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Campbell KL, Zadravec K, Bland KA, Chesley E, Wolf F, Janelsins MC (2020) The effect of exercise on cancer-related cognitive impairment and applications for physical therapy: systematic review of randomized controlled trials. Phys Ther. https://doi.org/10.1093/ptj/pzz090

  130. Freeman LW, White R, Ratcliff CG, Sutton S, Stewart M, Palmer JL, Link J, Cohen L (2015) A randomized trial comparing live and telemedicine deliveries of an imagery-based behavioral intervention for breast cancer survivors: reducing symptoms and barriers to care. Psychooncology 24(8):910–918. https://doi.org/10.1002/pon.3656

    Article  PubMed  Google Scholar 

  131. Milbury K, Chaoul A, Biegler K, Wangyal T, Spelman A, Meyers CA, Arun B, Palmer JL, Taylor J, Cohen L (2013) Tibetan sound meditation for cognitive dysfunction: results of a randomized controlled pilot trial. Psychooncology 22(10):2354–2363. https://doi.org/10.1002/pon.3296

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Hoffman CJ, Ersser SJ, Hopkinson JB, Nicholls PG, Harrington JE, Thomas PW (2012) Effectiveness of mindfulness-based stress reduction in mood, breast- and endocrine-related quality of life, and well-being in stage 0 to III breast cancer: a randomized, controlled trial. J Clin Oncol 30(12):1335–1342. https://doi.org/10.1200/jco.2010.34.0331

    Article  PubMed  Google Scholar 

  133. Johns SA, Brown LF, Beck-Coon K, Talib TL, Monahan PO, Giesler RB, Tong Y, Wilhelm L, Carpenter JS, Von Ah D, Wagner CD, de Groot M, Schmidt K, Monceski D, Danh M, Alyea JM, Miller KD, Kroenke K (2016) Randomized controlled pilot trial of mindfulness-based stress reduction compared to psychoeducational support for persistently fatigued breast and colorectal cancer survivors. Support Care Cancer 24(10):4085–4096. https://doi.org/10.1007/s00520-016-3220-4

    Article  PubMed  PubMed Central  Google Scholar 

  134. Alvarez J, Meyer FL, Granoff DL, Lundy A (2013) The effect of EEG biofeedback on reducing postcancer cognitive impairment. Integr Cancer Ther 12(6):475–487. https://doi.org/10.1177/1534735413477192

    Article  PubMed  Google Scholar 

  135. Johnston MF, Hays RD, Subramanian SK, Elashoff RM, Axe EK, Li J-J, Kim I, Vargas RB, Lee J, Yang L (2011) Patient education integrated with acupuncture for relief of cancer-related fatigue randomized controlled feasibility study. BMC Complement Altern Med 11(1):49

    Article  PubMed  PubMed Central  Google Scholar 

  136. Cimprich B (1993) Development of an intervention to restore attention in cancer patients. Cancer Nurs 16(2):83–92

    Article  CAS  PubMed  Google Scholar 

  137. Cimprich B, Ronis DL (2003) An environmental intervention to restore attention in women with newly diagnosed breast cancer. Cancer Nurs 26(4):284–292

    Article  PubMed  Google Scholar 

  138. Karschnia P, Parsons MW, Dietrich J (2019) Pharmacologic management of cognitive impairment induced by cancer therapy. Lancet Oncol 20(2):e92–e102. https://doi.org/10.1016/S1470-2045(18)30938-0

    Article  PubMed  Google Scholar 

  139. Kohli S, Fisher SG, Tra Y, Adams MJ, Mapstone ME, Wesnes KA, Roscoe JA, Morrow GR (2009) The effect of modafinil on cognitive function in breast cancer survivors. Cancer 115(12):2605–2616. https://doi.org/10.1002/cncr.24287

    Article  CAS  PubMed  Google Scholar 

  140. Lawrence J, Griffin L, Balcueva E, Groteluschen D, Samuel T, Lesser G, Naughton M, Case L, Shaw E, Rapp S (2016) A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy. J Cancer Surviv 10(1):176–184

    Article  CAS  PubMed  Google Scholar 

  141. Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, Choucair A, Fox S, Suh JH, Roberge D (2013) Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol 15(10):1429–1437

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  142. Chan AS, Cheung M-C, Law SC, Chan JH (2004) Phase II study of alpha-tocopherol in improving the cognitive function of patients with temporal lobe radionecrosis. Cancer 100(2):398–404. https://doi.org/10.1002/cncr.11885

    Article  CAS  PubMed  Google Scholar 

  143. Li X-J, Dai Z-Y, Zhu B-Y, Zhen J-P, Yang W-F, Li D-Q (2014) Effects of sertraline on executive function and quality of life in patients with advanced cancer. Med Sci Monit 20:1267–1273. https://doi.org/10.12659/MSM.890575

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  144. Ferguson RJ, Sigmon ST, Pritchard AJ, LaBrie SL, Goetze RE, Fink CM, Garrett AM (2016) A randomized trial of videoconference-delivered cognitive behavioral therapy for survivors of breast cancer with self-reported cognitive dysfunction. Cancer 122(11):1782–1791. https://doi.org/10.1002/cncr.29891

    Article  PubMed  Google Scholar 

  145. Park JH, Jung YS, Kim KS, Bae SH (2017) Effects of compensatory cognitive training intervention for breast cancer patients undergoing chemotherapy: a pilot study. Support Care Cancer 25(6):1887–1896. https://doi.org/10.1007/s00520-017-3589-8

    Article  PubMed  Google Scholar 

  146. Mar Fan HG, Clemons M, Xu W, Chemerynsky I, Breunis H, Braganza S, Tannock IF (2008) A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 16(6):577–583. https://doi.org/10.1007/s00520-007-0341-9

    Article  PubMed  Google Scholar 

  147. Lower EE, Fleishman S, Cooper A, Zeldis J, Faleck H, Yu Z, Manning D (2009) Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manag 38(5):650–662. https://doi.org/10.1016/j.jpainsymman.2009.03.011

    Article  CAS  Google Scholar 

  148. Escalante CP, Meyers C, Reuben JM, Wang X, Qiao W, Manzullo E, Alvarez RH, Morrow PK, Gonzalez-Angulo AM, Wang XS, Mendoza T, Liu W, Holmes H, Hwang J, Pisters K, Overman M, Cleeland C (2014) A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. Cancer J (Sudbury, Mass) 20(1):8–14. https://doi.org/10.1097/PPO.0000000000000018

    Article  CAS  Google Scholar 

  149. Lundorff L, Jønsson B, Sjøgren P (2009) Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial. Palliat Med 23(8):731–738. https://doi.org/10.1177/0269216309106872

    Article  CAS  PubMed  Google Scholar 

  150. Barton DL, Burger K, Novotny PJ, Fitch TR, Kohli S, Soori G, Wilwerding MB, Sloan JA, Kottschade LA, Rowland KM Jr, Dakhil SR, Nikcevich DA, Loprinzi CL (2013) The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Support Care Cancer 21(4):1185–1192. https://doi.org/10.1007/s00520-012-1647-9

    Article  PubMed  Google Scholar 

  151. Chang J, Couture FA, Young SD, Lau CY, Lee McWatters K (2004) Weekly administration of epoetin alfa improves cognition and quality of life in patients with breast cancer receiving chemotherapy. Support Cancer Ther 2(1):52–58. https://doi.org/10.3816/SCT.2004.n.023

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We acknowledge the valuable contribution of Rand Ajaj, who assisted in the formatting of this manuscript for publication.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Samantha J. Mayo.

Ethics declarations

Conflict of interest

Dr. Loprinzi reports personal fees from PledPharma, personal fees from Disarm Therapeutics, personal fees from Asahi Kasei, personal fees from Metys Pharmaceuticals, personal fees from OnQuality, personal fees from Mitsubishi Tanabe, personal fees from NKMax, personal fees from Novartis, outside the submitted work. All other authors declare that they have no conflict of interest.

Code availability

Not Applicable

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mayo, S.J., Lustberg, M., M. Dhillon, H. et al. Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group. Support Care Cancer 29, 2821–2840 (2021). https://doi.org/10.1007/s00520-020-05860-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-020-05860-9

Keywords

Navigation